These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 417019)

  • 21. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
    Isenman DE; Podack ER; Cooper NR
    J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies of human C5a as a mediator of inflammation in normal human skin.
    Yancey KB; Hammer CH; Harvath L; Renfer L; Frank MM; Lawley TJ
    J Clin Invest; 1985 Feb; 75(2):486-95. PubMed ID: 2982914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary injury induced by C3a and C5a anaphylatoxins.
    Stimler NP; Hugli TE; Bloor CM
    Am J Pathol; 1980 Aug; 100(2):327-48. PubMed ID: 6967702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM; Gleich GJ
    J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Inhibition of formation of complement C5-convertase].
    Kozlov LV; Lebedeva TV
    Bioorg Khim; 1998 May; 24(5):350-5. PubMed ID: 9661788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why do protease inhibitors enhance leucocyte migration inhibition to the antigen PPD?
    Burden AC; Stacey R; Wood RF; Bell PR
    Immunology; 1978 Dec; 35(6):959-62. PubMed ID: 310809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
    Baker PJ; Adler S; Yang Y; Couser WG
    J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.
    Vogt W; Schmidt G; Hinsch B
    Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
    Sobel AT; Cooper NR; Schreiber RD
    J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of anaphylatoxin formation by high-dose corticosteroids in total hip arthroplasty.
    Gammer W; Bengtson A; Heideman M
    Prog Clin Biol Res; 1989; 308():879-83. PubMed ID: 2789402
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isolation of three separate anaphylatoxins from complement-activated human serum.
    Hugli TE; Gerard C; Kawahara M; Scheetz ME; Barton R; Briggs S; Koppel G; Russell S
    Mol Cell Biochem; 1981 Dec; 41():59-66. PubMed ID: 6977086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.
    Fukuoka Y; Xia HZ; Sanchez-Muñoz LB; Dellinger AL; Escribano L; Schwartz LB
    J Immunol; 2008 May; 180(9):6307-16. PubMed ID: 18424754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proceedings: Cleavage of the third complement component (C3) and release of a spasmogenic, C3-derived peptide (C3a) by epsilon-aminocaproic acid (EACA) in serum: a process involving the complement activating properdin system.
    Vogt W; Schmidt G
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R103. PubMed ID: 4276668
    [No Abstract]   [Full Text] [Related]  

  • 35. Activation of complement by radiographic contrast media: generation of chemotactic and anaphylatoxin activities.
    Till G; Rother U; Gemsa D
    Int Arch Allergy Appl Immunol; 1978; 56(6):543-50. PubMed ID: 415989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors and conditions essential for activation of the fifth component of complement and release of anaphylatoxin (C5a).
    Vogt W; Schmidt G; von Buttlar B
    Monogr Allergy; 1977; 12():86-9. PubMed ID: 335222
    [No Abstract]   [Full Text] [Related]  

  • 37. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.
    Des Prez RM; Bryan CS; Hawiger J; Colley DG
    Infect Immun; 1975 Jun; 11(6):1235-43. PubMed ID: 806523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position.
    Seifert PS; Kazatchkine MD
    Mol Immunol; 1987 Dec; 24(12):1303-8. PubMed ID: 3431552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C3 and C5-cleaving properdin enzymes formed on zymosan incubated with human serum: the decay and the regeneration of the enzymes.
    Fujita T; Takiuchi M; Matsumoto M; Nagaki K; Inai S
    Int Arch Allergy Appl Immunol; 1977; 53(4):303-9. PubMed ID: 67089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The activation of human complement component C5 by a fluid phase C5 convertase.
    DiScipio RG; Smith CA; Muller-Eberhard HJ; Hugli TE
    J Biol Chem; 1983 Sep; 258(17):10629-36. PubMed ID: 6554279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.